GlassScriptPhysician profile
Amy Calderon
NPI 1821310004
$3,972.75
in general payments reported to CMS, 2019-2025
31 companies · $888 in 2025
The $888 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $197 · 2021: $568 · 2022: $683 · 2023: $555 · 2024: $1,083 · 2025: $888.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,512 · Education: $12.81.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,512.47 |
| Education | $12.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,830.75 | 2020-2025 | Mavyret, Rinvoq, Skyrizi |
| Takeda Pharmaceuticals U.S.A., INC. | $504.35 | 2021-2025 | Entyvio |
| Gilead Sciences, INC. | $191.09 | 2020-2025 | Livdelzi |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $183.24 | 2020-2025 | Xifaxan, Plenvu |
| Madrigal Pharmaceuticals | $174.36 | 2025 | Rezdiffra |
| Inari Medical, INC. | $121.30 | 2024 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Nestle Healthcare Nutrition INC. | $116.16 | 2021-2023 | |
| Aimmune Therapeutics, INC. | $111.36 | 2024-2025 | Zenpep |
| Intercept Pharmaceuticals, INC. | $85.75 | 2021-2023 | Ocaliva |
| Redhill Biopharma INC. | $77.13 | 2021-2022 | |
| Ironwood Pharmaceuticals, INC | $67.88 | 2021-2024 | |
| Phathom Pharmaceuticals, INC. | $59.89 | 2024-2025 | Voquezna |
| Merck Sharp & Dohme LLC | $53.40 | 2021-2024 | Dificid |
| Qol Medical, LLC | $46.69 | 2024-2025 | Sucraid, Sucraid |
| Dilon Technologies, INC. | $45.67 | 2025 | Hemoblast Bellows |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $42.77 | 2024-2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Boston Scientific Corporation | $29.25 | 2020-2023 | Rezum Generator |
| Novo Nordisk INC | $28.22 | 2020-2023 | |
| Amgen INC. | $25.93 | 2020 | |
| Biocon Biologics INC | $24.82 | 2024 | Hulio |
| Regeneron Healthcare Solutions, INC. | $17.27 | 2024 | Dupixent |
| Braintree Laboratories, INC. | $16.36 | 2024 | Suflave, Sutab |
| Boehringer Ingelheim Pharmaceuticals, INC. | $15.66 | 2023 | Cyltezo |
| Csl Behring | $15.56 | 2022 | |
| Ferring Pharmaceuticals INC. | $14.84 | 2025 | Adstiladrin |
| Ardelyx, INC. | $14.38 | 2025 | Ibsrela |
| Celgene Corporation | $12.03 | 2022 | |
| Alfasigma USA, INC. | $11.93 | 2021 | |
| Amarin Pharma, INC. | $11.81 | 2020 | |
| Astrazeneca Pharmaceuticals LP | $11.70 | 2020 | |
| Janssen Pharmaceuticals, INC | $11.20 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amy Calderon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.